Can Trevi make it through the IPO window with an old opioid that failed their key PhII?
The window for biotech IPOs may still be open, but is it open wide enough to accommodate Trevi Therapeutics, with a failed Phase II study for an extended-release version of an old opioid pain remedy?
Trevi filed for an $86 million IPO over the weekend. In it, they apparently revealed for the first time that their drug, nalbuphine ER, failed badly in a mid-stage study that recruited 63 patients and tested it at 2 doses compared to a placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.